Sign In
Buy PFE
$26.04
+0.350 (+1.36%)
At Close: Jun 05, 2026
3 Long-Term Stocks You'll Regret Not Buying Soon: November 2023
08:00am, Thursday, 16'th Nov 2023
Amidst the uncertainty, savvy investors recognize that market downturns potentially pave the way for future prosperity. However, the quest for long-term stocks to buy soon remains fraught with challen
AbbVie and Pfizer Have 1 Thing in Common: Their Biggest Products Are on the Decline. Time to Sell?
05:00am, Thursday, 16'th Nov 2023
AbbVie's top-selling drug, Humira, has lost exclusivity, and its sales are falling. Pfizer is seeing lower demand for its blockbuster coronavirus vaccine.
Yields Up To 10%: My Top 10 High Dividend Yield Companies For November
04:00pm, Wednesday, 15'th Nov 2023
While investing in companies that pay relatively high dividends provides you with several benefits, it often comes attached to an elevated risk-level. A careful selection process is essential for iden
15 A-Rated 6% Yielding SWANs Perfect For What's Coming Next
07:15am, Wednesday, 15'th Nov 2023
Americans are increasingly worried about job losses, and long-term inflation expectations are at a 12-year high. Leading economic indicators suggest a potential recession within three months, while un
Pfizer to halve UK workforce at Discovery Park
06:10am, Wednesday, 15'th Nov 2023
Pfizer Inc (NYSE:PFE) has said it will lay off more than half of its employees at a UK-based scientific research centre in Sandwich. The company intends to make cuts to its 940-strong workforce at
3 Undervalued Growth Stocks to Double Your Wealth in 2024
10:09pm, Tuesday, 14'th Nov 2023
While a certain confidence in betting with the masses exist, investors wanting to up the ante may consider undervalued growth stocks. To better frame the discussion, it's useful to consider the sport
Employer coverage of GLP-1 drugs for weight loss lags far behind diabetes coverage, survey finds
03:34pm, Tuesday, 14'th Nov 2023
For workers in employer-sponsored health plans, coverage of Wegovy and other GLP-1 medications for weight loss is lagging far behind coverage of that class of drugs for diabetes, a new survey shows.
Pfizer Layoffs 2023: What to Know About the Latest PFE Job Cuts
03:12pm, Tuesday, 14'th Nov 2023
Pharmaceutical giant Pfizer (NYSE: PFE ) has announced plans to cut jobs at its manufacturing plant in England as part of its ongoing cost-cutting measures. The layoff announcement comes a month after
Better Growth Stock: Pfizer vs. Novo Nordisk
09:45am, Tuesday, 14'th Nov 2023
Pfizer is looking to buy and develop new revenue drivers. Novo Nordisk aims to penetrate a profitable market even more.
4 high yields near 52-week lows worth looking at
06:05am, Tuesday, 14'th Nov 2023
Marketbeat's stock screening tools are a wealth of investment ideas, including the 52-week low list. Stocks trading at 52-week lows often provide oversold value ready to spring back, given the right c
Pfizer Stock Hits 3-Year Low—Down 50% From 2021 Peak
04:08pm, Monday, 13'th Nov 2023
Excluding a brief early 2020 plunge, Pfizer shares are now trading at their lowest level since 2016.
Pfizer stock dips as Swiss Biotech Basilea secures rights to Fosmanogepix
08:19am, Monday, 13'th Nov 2023
Swiss biotech Basilea Pharmaceutica (OTC:BPMUF) and Pfizer (NYSE:PFE) subsidiary Amplyx Pharmaceuticals have inked a deal worth $37 million, granting Basilea rights to Fosmanogepix, a Phase 3 ready br
Pfizer wants in on the weight loss drug market – and upcoming data will be crucial for its success
08:00am, Monday, 13'th Nov 2023
Analysts said upcoming data on Pfizer's obesity pill, danuglipron, will be crucial to how competitive the company can be against Eli Lilly and Novo Nordisk.
High-Quality Dividend Growth Near 52-Week Lows: Pfizer Is Phenomenal
05:47am, Sunday, 12'th Nov 2023
A list of high-quality dividend growth stocks is identified based on proximity to 52-week lows. Pfizer, Bristol-Myers Squibb, ResMed, and NextEra Energy appear attractively valued based on Future and
7 Undervalued Stocks With Potential to Hit Trillion-Dollar Milestone
03:49pm, Saturday, 11'th Nov 2023
When discussing the next trillion-dollar companies, this article will either be prescient or a total clown show. And while there's good evidence to suggest that I could sadly fall into the latter cate
